Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study (PERTAIN).
Mothaffar F. Rimawi
Research Funding - Genentech; GlaxoSmithKline
Christopher John Poole
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Other Remuneration - Roche
Jean-Marc Ferrero
No relevant relationships to disclose
Juan R. De la Haba Rodriguez
No relevant relationships to disclose
Lada Mitchell
Employment or Leadership Position - Roche
Christina H. Pelizon
Employment or Leadership Position - Roche
Stock Ownership - Roche
Grazia Arpino
Honoraria - GlaxoSmithKline; Roche
Other Remuneration - GlaxoSmithKline; Roche